Prevalence of Amlodipine‐Related Gingival Hyperplasia
Calcium channel blockers ar notable to contribute to animal tissue dysplasia. The overwhelming majority of reports discuss patients taking the drug Procardia. throughout the past few years a more moderen atomic number 20 channel blocker, amlodipine, has been used with increasing frequency. To date, six cases are printed indicating that amlodipine may additionally promote animal tissue hyperplasia; but, no knowledge are rumored concerning the prevalence of this development. the aim of this study was to look at an outsized cluster of patients taking amlodipine and confirm the prevalence of animal tissue dysplasia. 100 fifty rough patients WHO had been taking amlodipine, five mg per day for a minimum of half dozen months, volunteered to bear a screening examination for animal tissue dysplasia. delicate dysplasia. [1]
Amlodipine‐induced gingival overgrowth
Amlodipine could be a metal channel blocker employed in the management of angina and cardiovascular disease. we tend to report three cases of animal tissue overgrowth in adult rough patients related to chronic usage of this drug. animal tissue changes occurred among three months of indefinite quantity and seemed to be combined by the patient’s existing periodontic condition. all told three patients, there was sequestration of amlodipine in their crevicular fluid. the importance of this finding in regard to the pathologic process of this unwanted result remains to be elucidated. [2]
The pharmacokinetic profile of amlodipine
Amlodipine, a dihydropyridine Ca antagonist, was synthesized in a shot to develop a compound with a pharmacokinetic profile characteristic of this category, which might even have associate degree hyperbolic oral bioavailability and extended clearance time. one endovenous dose of ten mg resulted in associate degree absolute bioavailability of sixty fourth and a calculated elimination half-life of thirty four hours. The pharmacokinetic profile of oral doses showed similar changes. These results were considerably completely different from those seen with most alternative dihydropyridines (elimination half-life of three to ten hours and absolute bioavailability of 100 percent to 30%) and nondihydropyridine Ca antagonists (elimination half-life 3 to six hours and low absolute bioavailability). With chronic oral dosing of amiodipine once daily for fourteen days, support was provided for the dimensionality of amlodipine’s pharmacological medicine and absence of such with chronic oral dosing with calcium blocker, diltiazem, and Procardia. [3]
The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily
The objective of this clinical test double-blind parallel-group controlled study was to look at the prevalence of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with force per unit area|hypertension} whose pulsation blood pressure (SBP) had not reached the therapeutic target levels. [4]
The Management of Amlodipine-induced Gingival Overgrowth Associated to Generalized Chronic Periodontitis- A Case Report
This case report describes the management of AN sixty years-old feminine WHO given with generalized chronic disease related to amlodipine-induced animal tissue overgrowth. The clinical examination showed generalized dropsical animal tissue tissues, with animal tissue overgrowth, and presence of dental plaque and calculus on the surfaces of the teeth. Patient was a acknowledged hypertensive, and he or she was on medication with amlodipine from past 3 years. diagnosing decided supported history, clinical findings and picture taking examination. With the consent of medical man for substitution of amlodipine, treatment consisted of meticulous oral hygiene instruction, scaling, root surface instrumentation, bar, and daily antiseptic mouth rinses. when this stage, dental medicine surgery for pockets and excess animal tissue tissues elimination was performed. The patient has been registered in a very appurtenant dental medicine maintenance program, and when 3-years, there has been no repetition. [5]
Reference
[1] Jorgensen, M.G., 1997. Prevalence of amlodipine‐related gingival hyperplasia. Journal of periodontology, 68(7), (Web Link)
[2] Seymour, R.A., Ellis, J.S., Thomason, J.M., Monkman, S. and Idle, J.R., 1994. Amlodipine‐induced gingival overgrowth. Journal of clinical periodontology, 21(4), (Web Link)
[3] Abernethy, D.R., 1989. The pharmacokinetic profile of amlodipine. American heart journal, 118(5), (Web Link)
[4] The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily
T Fujiwara, Y Ii, J Hatsuzawa, H Murase, T Watanabe, M Murakami, N Kimura, J Buch, T Tsuchihashi & T Saruta
Journal of Human Hypertension volume 23, (Web Link)
[5] Renzo, G., Dario, D., Gianfranco, G., Gabriele, M. and Luca, T. (2018) “The Management of Amlodipine-induced Gingival Overgrowth Associated to Generalized Chronic Periodontitis- A Case Report”, International Journal of Medical and Pharmaceutical Case Reports, 11(1), (Web Link)
